BioSpace News Archive

NeoDynamics AB (Nasdaq First North Growth Market Stockholm: NEOD.ST), a medical device company dedicated to advancing the diagnosis and care of cancer, announced today that it is launching the NeoNavia biopsy system configured with its FlexiPulse probe in the United States to support the diagnosis of cancer.

Triumvira Immunologics today announced the appointment of Robert Williamson as President and Chief Business Officer.

JSR Life Sciences, LLC (JSR) and Blau Farmaceutica (Blau) (public company in Brazil B3 – BLAU3) today announced that Similis Bio (“Similis”), its recently launched business unit focused on biosimilar development, has signed its first development and license agreement with Blau Farmacêutica (“Blau”).

Alto Neuroscience today announced the closing of a $35 million Series B financing led by Lightswitch Capital and partners of Alkeon Capital.

Castle Biosciences, Inc. today announced new data showing that the use of TissueCypher® Barrett’s Esophagus Test results can significantly improve management decisions for Barrett’s esophagus (BE) patients with low-grade dysplasia (LGD) to improve health outcomes.

Normunity, Inc., a biotechnology company creating novel precision anti-cancer immunotherapies, today announced its launch and Series A financing of $65 million.

CorVista Health, Inc, a digital health company dedicated to improving cardiovascular disease diagnosis, announces that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the CorVista System as a first non-invasive point of care diagnostic solution for patients with suspected pulmonary hypertension.

Aclarion, Inc. will be presenting at the 15th annual LD Micro Main Event on Tuesday, October 25th at 9:00 AM PT at the Luxe Sunset Boulevard Hotel in Los Angeles.

Soligenix, Inc. announced today the formation of a Medical Advisory Board (MAB) to provide medical/clinical strategic guidance to the Company as it advances the Phase 2a clinical development of SGX302 (synthetic hypericin) for the treatment of mild-to-moderate psoriasis.

Proteros biostructures GmbH announced that it has initiated a multi-target drug discovery partnership with Adrestia Therapeutics, a leader in synthetic rescue therapies for genetic diseases.